Gujarat Terce Laboratories Limited · BSE:GUJTERC
Gujarat Terce Laboratories — Q4 FY2023 Earnings Presentation
11 slides from Gujarat Terce Laboratories's earnings presentation, Jun 1, 2023
Slide 1: Gujarat Terce Laboratories Limited
GUJARAT TERCE 44 LABORATORIES LIMITED
Slide 2: Disclaimer
Disclaimer This presentation is for informational purposes only and does not constitute an offer or a solicitation to sell or an edition or a solicitation to submit an offer to purchase or subscribe for shares or securities of Gujarat Terce Laboratories Limited or a portion thereof, constitute the b
Slide 3: Company Overview
Company Overview Gujarat Terce has over 3 decades of experience in the Manufacturing and Marketing of branded Generics. Roots of Gujarat Terce Laboratories Limited are entrenched in the founding principles of COMPASSION and EXCELLENCE. Terce has an extensive basket of 50 Brands (125 products) with a
Slide 4: Business Highlights
Business Highlights Figures= % of total sales Figures= % of total sales 80 80 78 77 76 61 Q4FY22 39 60 Acute Segment 60 Other Brands Q4FY23 40 Chronic Segment Precious Brands 40 23 22 24 63 20 20 FY22 37 59 FY23 41 0 Q4FY22 Q4FY23 FY22 FY23 0 25 50 75 Comparing Q4FY23 vs Q4FY22 data: Our focus on gr
Slide 5: Business Highlights- PCPM (Per Capita Per Month)
Business Highlights- PCPM (Per Capita Per Month) 2.5 2.11 2 1.96 1.63 The Expansion in geopraphies that we 1.48 did in this FY, has started reflecting in 1.5 revenues and we will be consistently growing productivity per medical 1 representative, thus ensuring pathway towards profitability. 0.5 0 Q4F
Slide 6: Business Highlights- Sales of Top Four Brands
Business Highlights- Sales of Top Four Brands Figures in lacs 1,000 965 400 386 822 773 750 300 288 240 500 461 200 114 250 100 0 0 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Therapeutic Segment- Anticold Therapeutic Segment- Pain Management Type- Acute Type- Acute
Slide 7: Business Highlights- Sales of Top Four Brands
Business Highlights- Sales of Top Four Brands Figures in lacs 150 138 300 286 129 208 100 94 200 171 74 145 50 100 0 0 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Therapeutic Segment- Nutraceutical Therapeutic Segment- Vitamins ( Nutraceuticals) Type- Acute Type- Chronic
Slide 8: Distribution Network & Region Wise Sales
Distribution Network & Region Wise Sales North 23.8% 17 6 105 139 28 75 75 West 12 1 55.2% 18 Central 21% 1 3 1 Stockists/ Region-wise sales distribution(FY23) Distributors
Slide 9: Financial Highlights- Q4 FY23 and FY 23
Financial Highlights- Q4 FY23 and FY 23 Q4FY23 38% 94% 148% YoY growth Op revenue EBIDTA PAT FY23 16.57% -238.30% -291.63% YoY growth Op revenue EBIDTA PAT Gujarat Terce has grown by 38% in Q4FY23 compared to Q4FY22. Cash Profit registered by business has increased by 162 % in Q4FY23 vs Q4FY22
Slide 10: Q4FY23 AND FY 23- Income Statement
Q4FY23 AND FY 23- Income Statement (Rs. In Lacs) Q-O-Q Y-O-Y Y-O-Y Q4 Q3 Q4 Year Year Particulars Q4 vs. Q3 Q4 vs. Q4 % Change 2022-23 2022-23 2021-22 ended 31-03-2023 ended 31-03-2022 % Change % Change (2023 vs 2022) Revenue from 1288.85 1190.48 8.26% 932.45 38% 4,678.25 4,013.37 16.57% Operations
Slide 11: Thank you.
Thank you. Registered Office: Gujarat Terce Laboratories Limited, 122/2 Ravi Estate, Bileshwarpura, Chhatral, T.A.: Kalol, Gandhinagar, Gujarat 382729 Corporate office: D/ 801 - 802 & 1202, The First, Behind Keshavbaug Party Plot, Near Shivalik High- Street, Vastrapur, Ahmedabad, Gujarat 380015 Inve
Gujarat Terce Laboratories — Q4 FY2023 Earnings Presentation on 6ix